

Docket No.: 65324US(51697)
(PATENT)
Express Mail No.: EV 756034715 US

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)
(National Phase of International Appln.: PCT/NZ2004/000247
Publication No. WO2005/033131 A1)

In re Patent Application of:
Grant N. Larson, *et al.*

International Application No.: PCT/NZ05/000247

International Filing Date: October 11, 2004

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: AMYLOID FORMATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents, which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have previously been transmitted

Application No. Not Yet Assigned
U.S. National Phase of PCT/NZ2004/000247
Preliminary Amendment

Docket No.: 65324US(51697)
Express Mail No.: EV 756034715 US


by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent application No. PCT/NZ 2004/000247, filed October 11, 2004. A copy of the International Search Report is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants submit that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62138US(49949). A duplicate copy of this paper is enclosed.

Dated: April 6, 2006

Respectfully submitted,


By
Peter C. Lauro
Registration No.: 32,360
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorneys/Agents For Applicants

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Grant N. Larson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	65324US(51697)
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite. No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite. No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA**	-WO 2000/017328-A2	03-30-2000	ISIS INNOVATION LIMITED	Pages 3-5	
	BB**	-WO 2002/042321-A2	05-30-2002	ISIS INNOVATION LIMITED	Whole Document	
	BC**	-WO 2001/027152-A1	04-19-2001	ISIS INNOVATION LIMITED	See especially pages 24, 26, Example 9	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite. No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA**	Chen S et al, "Amyloid-like features of Polyglutamine Aggregates and their assembly Kinetics", Biochemistry, Vol. 41, 2002, p 7391-7399 Whole Document	
	CB**	Takahashi Y et al, "Mutational analysis of designed peptides that undergo structural transition from α helix to β sheet and amyloid fibril formation", Structure with Folding & Design, Vol 8 (9), 15 September 2000, pages 915-925 Whole Document	
	CC**	Takahashi Y et al, "Amyloid Architecture: Complimentary Assembly of Heterogeneous Combinations of Three or Four Peptides into Amyloid Fibrils," Chembiochem: a European Journal of Chemical Biology, Vol, 3 (7), 2 July 2002, pages 637-642 Whole Document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------